Nobizide (Hydrochlorothiazide, Nebivolol)

Hydrochlorothiazide acts on the distal convoluted tubule of the kidney, inhibiting sodium‑chloride reabsorption and promoting diuresis, which reduces plasma volume. Nebivolol selectively blocks β1‑adrenergic receptors, decreasing heart rate and contractility, while also enhancing nitric‑oxide release for vasodilation. Together they lower peripheral resistance and blood pressure.

The appropriate dose of Nobizide is determined by the prescribing healthcare professional based on the individual’s blood‑pressure profile, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Nobizide in pregnancy or while breastfeeding has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Nobizide, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nobizide offers a fixed‑dose combination of a thiazide diuretic and a β1‑selective blocker, which can simplify regimens compared with taking two separate agents. This may improve adherence and provide complementary mechanisms of action, whereas monotherapy with either class alone might be less effective in patients requiring multiple pathways to achieve target blood pressure.

Nobizide tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the packaging.

Nobizide is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe electrolyte disturbances (especially low potassium), acute kidney injury, marked hypotension that can cause dizziness or fainting, and allergic reactions such as rash, angioedema, or anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like rapid weight gain, muscle cramps, severe weakness, or swelling of the face and throat.

Nobizide should be avoided in individuals with known hypersensitivity to either component, severe renal impairment, or uncontrolled electrolyte abnormalities. Caution is also advised for patients with severe liver disease, recent myocardial infarction, or those taking medications that may cause dangerous interactions. A healthcare professional must evaluate suitability before prescribing.